论文部分内容阅读
高脂血症８９例随机按２∶１分成二组，一组５７例，每日晚餐后服普拉固１０ｍｇ；另一组３２例，每日晚餐后服脂康平０．４ｇ，疗程均为８周。与服药前比，服普拉固８周后，血清ＴＣ、ＴＧ及（ＴＣ－ＨＤＬＣ）／ＨＤＬＣ分别下降１４．５％、２１．６％及２４．９％，ＨＤＬＣ升高２０．５％（Ｐ均＜０．００１）；服脂康平８周后，血清ＴＧ降４０．６％（Ｐ＜０．００１），ＨＤＬＣ升２３．１％（Ｐ＜０．００１），（ＴＣ－ＨＤＬＣ）／ＬＤＬＣ降２１．６％（Ｐ＜０．０１），ＴＣ升３．３％（Ｐ＞０．０５）。两组间比，普拉固降ＴＣ明显优于脂康平，而脂康平降ＴＧ则明显优于普拉固，均有非常显著的统计学差别（Ｐ均＜０．００１）。所测其他指标，两组间虽也有差异，但均未见有统计学意义（Ｐ均＞０．０５）。
89 cases of hyperlipidemia randomly divided into 2 groups according to 2: 1, a group of 57 cases, daily pradiprazole 10mg dinner; another group of 32 cases, daily sufetidyxapine 0.4g after treatment were 8 weeks. Compared with the medication before, after taking Prasugrel for 8 weeks, serum TC, TG and (TC-HDL-C) / HDL-C decreased by 14.5%, 21.6% and 24.9%, HDL-C Serum TG decreased 40.6% (P <0.001) and HDL-C increased 23.1% (P <0.001) ), (TC-HDL-C) / LDL-C decreased by 21.6% (P <0.01) and TC increased by 3.3% (P> 0.05). The difference between the two groups was statistically significant (P <0.001). Pseudo-solid decreased TC significantly better than that of Zhikangping, while Zhikang-Ping reduced TG significantly better than Prasuga. Other indicators measured, although there are differences between the two groups, but no statistically significant (P all> 0.05).